Wang 2008.

Methods	no washout required because no participant received lipid‐lowering agents 2‐month randomised placebo‐controlled trial
Participants	120 men and women with acute cerebral infarction and hyperlipidaemia TC > 5.72 mmol/L (221 mg/dL) LDL‐C > 3.64 mmol/L (141 mg/dL) HDL‐C < 1.0 mmol/L (39 mg/dL) TG > 1.7 mmol/L ( 151 mg/dL) exclusion criteria: severe liver disease, renal disease, statin hypersensitivity and lack of compliance Placebo baseline TC : 5.47 mmol/L (212 mg/dL) Placebo baseline LDL‐C : 2.89 mmol/L (112 mg/dL) Placebo baseline triglycerides: 2.27 mmol/L (201 mg/dL) Fluvastatin 40 mg/day baseline TC : 5.48 mmol/L (212 mg/dL) Fluvastatin 40 mg/day baseline LDL‐C : 2.91 mmol/L (113 mg/dL) Fluvastatin 40 mg/day baseline triglycerides: 2.29 mmol/L (203 mg/dL)
Interventions	Placebo Fluvastatin 40 mg every night Xuezhikang 0.6 mg twice daily
Outcomes	per cent change from baseline at 2 months of blood TC, LDL‐C and triglycerides
Source of Funding	unknown
Notes	Xuezhikang 0.6 mg twice daily group was not included in the efficacy analysis WDAEs were not reported SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random sequence generation method not reported
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of proper blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	WDAEs were not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported